←
Katherine Bridge, PhD797 posts
Katherine Bridge, PhD avatar

Katherine Bridge, PhD

@BridgeKatherine

Principal Investigator // Blood Cancer Researcher // Cell Biologist // Innovator // @young_EHA @ISEHsociety committees // Mum of 3 // Bring coffee

◷ Joined February 2012▧ 137 Photos and videos
Katherine Bridge, PhD avatar
Katherine Bridge, PhD@BridgeKatherine·20 Nov 2024

It was a pleasure to host you @bloodcancer_uk today @CBR_UoY. Thank you for all you do for people with blood cancer, for your insightful questions, enthusiasm and a humbling, humanising refresh on why we do what we do. @hitchcock_lab @AdeleKFielding #bloodcancer #research

Trustees at @bloodcancer_uk got a brilliant tour of the Centre for Blood Research at @UniOfYork with Prof Ian Hitchcock, @BridgeKatherine and the team today. Great to see funding translated into science!

Post attachmentPost attachmentPost attachment
York Biomedical Research Institute avatar
⟳ Katherine Bridge, PhD retweeted
York Biomedical Research Institute@YBRI_UoY·4 Nov 2024

Fully funded PhD opportunity @DiMeN_DTP @JNB_lab @BridgeKatherine @mjplevin @Labcorp @CBR_UoY Enhancing LNP-RNA delivery to leukemia cells through cutting-edge cryogenic electron tomography (cryo-ET) #DiMeN #CancerResearch Deadline: 13/12/24 findaphd.com/phds/project/mr…

Katherine Bridge, PhD avatar
Katherine Bridge, PhD@BridgeKatherine·30 Sep 2024

My feed here now mostly drowns out the posts I actually care about with randomness, so I'm migrating over to LinkedIn. My profile is below, connect with me and I'll see you on the other side! linkedin.com/in/katherine-br…

Katherine Bridge, PhD avatar
Katherine Bridge, PhD@BridgeKatherine·5 Sep 2024

And finally, thank you to the most important and all-twitterless stars working with me David Kealy, Ruth Ellerington, Cathy Hawley, Gillian Caalim, Jakub Lukaszonek, Nicole-Mae Blacknell and Bryce Drylie.

Katherine Bridge, PhD avatar
Katherine Bridge, PhD@BridgeKatherine·5 Sep 2024

Our study defines that the modality of HIF-1 activation substantially alters its function, identifying pathogenic HIF-1 signatures, and restoring the potential for therapeutic targeting of HIF-1 that spare its essential oxygen homeostatic function.